Results 111 to 120 of about 31,918 (237)
Cancer Medicine, Volume 15, Issue 1, January 2026.PV‐R‐CHP showed improved progression‐free and overall survivals compared to R‐CHOP‐based regimens in newly diagnosed Japanese patients with DLBCL, particularly in those with non‐GCB subtype. These results were consistent in both the overall cohort and propensity score‐matched cohorts.
Masaaki Hotta +8 more
wiley +1 more source
Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use [PDF]
, 2015 Derek Weycker +9 more
openalex +1 more source
A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study [PDF]
, 2021 Yu Zhu +4 more
openalex +1 more source
Cancer Medicine, Volume 15, Issue 1, January 2026.ABSTRACT Introduction Standard therapy for PD‐1 inhibitor‐refractory recurrent or metastatic head and neck squamous‐cell carcinoma (RM‐HNSCC) has limited activity. Drugs bound to albumin selectively target cancer cells with upregulated macropinocytosis, a process driven by constitutively hyper‐activated EGFR/RAS/PIK3CA signaling, which is common in ...
Douglas Adkins +6 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Sinomenine, derived from Sinomenium acutum, is widely used in inflammatory diseases. However, its risk of inducing agranulocytosis is not widely appreciated. We report a life‐threatening case in a 40‐year‐old woman with chronic kidney disease (CKD; baseline estimated glomerular filtration rate [eGFR] as low as 36 mL/min/1.73 m2) who developed ...
Ping Xin, Ruoyan Liu, Yu Zhang, Bin Fu
wiley +1 more source
Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia [PDF]
, 2019 Hartmut Link
openalex +1 more source
Cancer, Volume 132, Issue 1, 1 January 2026.Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Marina Konopleva +10 more
wiley +1 more source
Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer [PDF]
, 2001 G. Fleischhack
openalex +1 more source
Efficacy of Joungal in preventing febrile neutropenia induced by platinum-based doublet chemotherapy in lung cancer [PDF]
, 2020 Fanxu Zeng +9 more
openalex +1 more source
Cancer Reports, Volume 9, Issue 1, January 2026.ABSTRACT Background Refractory/relapsed acute myeloid leukemia (R/R‐AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the primary treatment option in such patients.
Yufeng Du +6 more
wiley +1 more source